25550 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 09
00:49 UTC
|
CNQ
Canadian Natural Resources
|
◎ Target | firm only | Buy | C$72.00→ C$73.00+1.4% |
|
Aug 09
00:49 UTC
|
CNQ
Canadian Natural Resources
|
◎ Target | firm only | Sec→ r Perform | C$71.00→ C$73.00+2.8% |
|
Aug 09
00:49 UTC
|
CMPX
Compass Therapeutics
|
◎ Target | Biren Amin ★★☆☆☆ #2416 | Overweight | $4.00→ $6.00+50.0% |
|
Aug 09
00:49 UTC
|
CMPS
Compass Pathways
|
◎ Target | Patrick R. Trucchio not yet tracked | Buy | $70.00→ $65.00-7.1% |
|
Aug 09
00:49 UTC
|
CMC
Commercial Metals
|
◎ Target | Richard Garchitorena ★★★☆☆ #2061 | Equal Weight | $75.00→ $80.00+6.7% |
|
Aug 09
00:49 UTC
|
CLYM
Climb Bio
|
◎ Target | Danielle Brill ★★★☆☆ #2117 | Buy | $17.00→ $25.00+47.1% |
|
Aug 09
00:49 UTC
|
CLS
Celestica
|
◎ Target | Tim Long ★★★☆☆ #1812 | Overweight | $430.00→ $406.00-5.6% |
|
Aug 09
00:49 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Etzer Darout ★★★☆☆ #2050 | Overweight | $48.00→ $53.00+10.4% |
|
Aug 09
00:49 UTC
|
CLDX
Celldex Therapeutics
|
◎ Target | Judah Frommer ★★★☆☆ #2195 | Overweight | $40.00→ $46.00+15.0% |
|
Aug 09
00:49 UTC
|
CIFR
Cipher Mining
|
◎ Target | Richard Choe ★★★☆☆ #1061 | Overweight | $23.00→ $22.00-4.3% |
|
Aug 09
00:49 UTC
|
CHYM
Chime Financial
|
◎ Target | Nik Cremo ★★★☆☆ #1049 | Overweight | $26.00→ $33.00+26.9% |
|
Aug 09
00:49 UTC
|
CGON
CG Oncology
|
◎ Target | Leonid Timashev ★★★☆☆ #1232 | Outperform | $81.00→ $79.00-2.5% |
|
Aug 09
00:49 UTC
|
CGON
CG Oncology
|
◎ Target | Kelsey Goodwin ★★★★☆ #563 | Overweight | $82.00→ $85.00+3.7% |
|
Aug 09
00:49 UTC
|
CGON
CG Oncology
|
◎ Target | Gregory Renza ★★☆☆☆ #2491 | Buy | $82.00→ $85.00+3.7% |
|
Aug 09
00:49 UTC
|
CGNX
Cognex
|
◎ Target | Jamie Cook ★★☆☆☆ #2225 | Hold | $71.00→ $78.00+9.9% |
|
Aug 09
00:49 UTC
|
CGNX
Cognex
|
◎ Target | Troy Jensen ★★★☆☆ #1111 | Overweight | $76.00→ $84.00+10.5% |
|
Aug 09
00:49 UTC
|
CGNX
Cognex
|
◎ Target | James Ricchiuti ★★★★☆ #895 | Buy | $75.00→ $80.00+6.7% |
|
Aug 09
00:49 UTC
|
CF
CF Industries
|
◎ Target | Joshua Spector ★★★☆☆ #1127 | Neutral | $115.00→ $123.00+7.0% |
|
Aug 09
00:49 UTC
|
CELH
Celsius
|
◎ Target | Andrea Teixeira not yet tracked | Overweight | $56.00→ $52.00-7.1% |
|
Aug 09
00:49 UTC
|
CELH
Celsius
|
◎ Target | Filippo Falorni ★★★☆☆ #1268 | Buy | $50.00→ $40.00-20.0% |
|
Aug 09
00:49 UTC
|
CELH
Celsius
|
◎ Target | Michael Lavery ★★★☆☆ #1785 | Overweight | $49.00→ $36.00-26.5% |
|
Aug 09
00:49 UTC
|
CDRE
Cadre
|
◎ Target | Tomohiko Sano ★★★★☆ #348 | Overweight | $40.00→ $45.00+12.5% |
|
Aug 09
00:49 UTC
|
CCOI
Cogent Communications
|
◎ Target | Gregory Williams ★★★☆☆ #1994 | Buy | $34.00→ $30.00-11.8% |
|
Aug 09
00:49 UTC
|
CCOI
Cogent Communications
|
◎ Target | Eric Luebchow ★★★★☆ #350 | Equal Weight | $18.00→ $14.00-22.2% |
|
Aug 09
00:49 UTC
|
CCOI
Cogent Communications
|
◎ Target | Brandon Nispel ★★★★☆ #560 | Overweight | $25.00→ $15.00-40.0% |
|
Aug 09
00:49 UTC
|
CBT
Cabot
|
◎ Target | Jeffrey Zekauskas ★★★★★ #310 | Underweight | $70.00→ $78.00+11.4% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Deepak Mathivanan ★★★★☆ #416 | Overweight | $56.00→ $63.00+12.5% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Bernie McTernan ★★★★☆ #601 | Buy | $55.00→ $63.00+14.5% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Jason Helfstein ★★★☆☆ #2102 | Outperform | $60.00→ $65.00+8.3% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Ken Gawrelski ★★★☆☆ #1599 | Equal Weight | $47.00→ $54.00+14.9% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Taylor Manley not yet tracked | Neutral | $44.00→ $46.00+4.5% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Doug Anmuth ★★★☆☆ #1099 | Overweight | $55.00→ $62.00+12.7% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Mark Zgutowicz ★★★★☆ #859 | Buy | $55.00→ $63.00+14.5% |
|
Aug 09
00:49 UTC
|
CART
Maplebear
|
◎ Target | Ross Sandler ★★★☆☆ #1748 | Overweight | $69.00→ $77.00+11.6% |
|
Aug 09
00:49 UTC
|
CARS
Cars.com
|
◎ Target | Joseph Spak ★★★☆☆ #1393 | Neutral | $12.00→ $13.00+8.3% |
|
Aug 09
00:49 UTC
|
CARG
CarGurus
|
◎ Target | Brad Erickson ★★☆☆☆ #2357 | Outperform | $35.00→ $42.00+20.0% |
|
Aug 09
00:49 UTC
|
CARG
CarGurus
|
◎ Target | Kunal Madhukar ★☆☆☆☆ #2900 | Neutral | $37.00→ $40.00+8.1% |
|
Aug 09
00:49 UTC
|
CARG
CarGurus
|
◎ Target | Marvin Fong ★★☆☆☆ #2581 | Buy | $40.00→ $41.00+2.5% |
|
Aug 09
00:49 UTC
|
CARG
CarGurus
|
◎ Target | Chris Pierce ★★★☆☆ #1808 | Buy | $43.00→ $44.00+2.3% |
|
Aug 09
00:49 UTC
|
CACI
CACI International
|
◎ Target | Gavin Parsons ★★★☆☆ #1064 | Buy | $598.00→ $804.00+34.4% |
|
Aug 09
00:49 UTC
|
CACI
CACI International
|
◎ Target | Seth Seifman ★★★★★ #181 | Overweight | $645.00→ $715.00+10.9% |
|
Aug 09
00:49 UTC
|
CABO
Cable One
|
◎ Target | Gregory Williams ★★★☆☆ #1994 | Hold | $111.00→ $86.00-22.5% |
|
Aug 09
00:49 UTC
|
BTMD
biote
|
◎ Target | Jonna Kim ★★★☆☆ #1343 | Buy | $2.50→ $2.00-20.0% |
|
Aug 09
00:49 UTC
|
BSY
Bentley Systems
|
◎ Target | firm only | Outperform | $41.00→ $43.00+4.9% |
|
Aug 09
00:49 UTC
|
BP
BP
|
◎ Target | John Royall not yet tracked | Neutral | $42.00→ $43.00+2.4% |
|
Aug 09
00:49 UTC
|
BOS
AirBoss of America
|
◎ Target | firm only | Buy | C$10.00→ C$11.00+10.0% |
|
Aug 09
00:49 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Mitchell S. Kapoor not yet tracked | Neutral | $50.00→ $60.00+20.0% |
|
Aug 09
00:49 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Leland Gershell ★★★★☆ #586 | Outperform | $95.00→ $97.00+2.1% |
|
Aug 09
00:49 UTC
|
BMRN
BioMarin Pharmaceutical
|
◎ Target | Matthew Harrison not yet tracked | Overweight | $119.00→ $124.00+4.2% |
|
Aug 09
00:49 UTC
|
BMBL
Bumble
|
◎ Target | Brad Erickson ★★☆☆☆ #2357 | Sec→ r Perform | $5.00→ $4.00-20.0% |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.